FDA Warns GLP1 Drugs Eye Risks

FDA Warns GLP1 Drugs Eye Risks CNN‑News18 released a video on its YouTube channel detailing new safety concerns raised by the U.S. Food and Drug Administration (FDA) about a class of weight‑loss and diabetes medicines known as GLP‑1 receptor agonists. The segment focuses on the potential for a rare eye condition called anterior ischemic optic neuropathy (AION) and examines the rapid growth of the market for these drugs in India. The FDA has added a warning to the prescribing information for several GLP‑1 products, including Ozempic, Wegovy, Mounjaro and Rybelsus, after reviewing data from more than 126 clinical trials involving over 130,000 participants. The agency found an incidence of roughly 6.4 cases of AION per 100,000 patient‑years among GLP‑1 users, compared with 3.8 cases for patients on other treatments. The difference translates to about 2.6 additional cases per 100,000 patient‑years. While the absolute risk is small, the condition can cause sudden, painless loss of vision in one eye and may be irreversible. “People taking these medicines should watch for any sudden blurry vision, loss of vision in one eye, blind spots or unusual changes in color perception and seek medical help immediately,” the video’s host said. The segment notes that the FDA has not banned the drugs, emphasizing that their benefits for obesity and type‑2 diabetes still outweigh the identified risk for many patients. India’s market for anti‑obesity medicines has surged since the first GLP‑1 product arrived in March 2025. Sales rose from roughly 571 crore rupees in the first year to an estimated 1,230 crore rupees a year later, more than doubling as generic versions entered the market after the semaglutide patent expired. More than 40 manufacturers now produce the drugs, making them widely available and prompting concerns about unsupervised use for cosmetic weight loss. Reu Puri, co‑founder of Nivi AI, cautioned that “the studies are recent and limited to less than half a decade, but we cannot ignore the leanings toward eye issues, especially in patients with existing comorbidities.” He urged regular eye examinations for anyone on GLP‑1 therapy, regardless of whether they experience symptoms. Dr. Ishwar Gilada, secretary general of the People’s Health Organization, added that “any new drug will eventually reveal side effects once used by millions.” He emphasized proper patient selection and warned that the drugs’ affordability has led to a “herd mentality” in India, with many individuals obtaining prescriptions without thorough medical evaluation. “When a medication becomes cheap and easily accessible, the risk of misuse rises, and that can result in sudden, painless blindness,” he said. The video notes that regulators in Europe, Australia, Canada and the United States have already incorporated the eye‑stroke warning into drug labeling. It asks whether Indian authorities will follow suit as the market expands. Health experts advise patients to discuss the warning with their physicians, weigh the benefits against the small but serious eye‑risk, and consider lifestyle interventions such as diet and exercise as complementary or alternative strategies for weight management. The FDA’s action underscores the need for ongoing vigilance as novel therapies reach broader populations worldwide.